(Q54248808)
Statements
Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. (English)
1 reference
Carella AM
1 reference
Carlier P
1 reference
Pungolino E
1 reference
Resegotti L
1 reference
Liso V
1 reference
Stasi R
1 reference
Montillo M
1 reference
Iacopino P
1 reference
Mirto S
1 reference
Pagano L
1 reference
1 February 1993
1 reference
1 reference
7
1 reference
2
1 reference
196-199
1 reference
Identifiers
1 reference